Program Overview

This dynamic and insightful program brings the patient voice to the forefront, highlighting the real-world impact of chronic immune thrombocytopenia (cITP) on quality of life (QOL) and health outcomes. This engaging activity is designed to equip healthcare providers with practical strategies to enhance patient collaboration in treatment decision-making, offering actionable resources to support the process. We will review new and emerging therapeutic options for managing persistent/chronic ITP, providing in-depth clinical profiles of the latest advancements. Gain valuable insights into how to address your patients' most frequent concerns regarding these therapies, empowering you to better guide them through their treatment journey.


Learning Objectives

Upon completion of this activity, the learners should be able to:

  • Demonstrate understanding of the impact of cITP on patients
  • Outline for a patient the benefits and risks of current treatment approaches for cITP
  • Address common patient concerns regarding emerging cITP treatment options


CME Accreditation:

Accreditation Type:

  • Physicians—maximum of 1.0 AMA PRA Category 1 Credit(s)™
  • Nurses—1.0 contact hours of nursing continuing professional development credit
  • Pharmacists–1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit
  • PAs—maximum of 1.0 AAPA Category 1 CME credits


Instructions for Participation and Requesting Credit:

There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity, and completing the post-test and evaluation form.


Credit Fulfillment

  • If you are requesting AMA credits, ANCC credits, AAPA credits, or a certificate of participation, your certificate will be available for download.
  • If you are a pharmacist requesting ACPE credits, your credit request will be uploaded to CPE Monitor within 60 days.


    • Accredited Provider

    This activity is jointly provided by The France Foundation, the International Society on Thrombosis and Haemostasis, and the Platelet Disorder Support Association.